Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.61
-0.09 (-1.67%)
Sep 2, 2026, 11:43 AM EDT - Market open
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $5.49M in the twelve months ending June 30, 2026, down -32.27% year-over-year. In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth.
Revenue (ttm)
$5.49M
Revenue Growth
-32.27%
P/S Ratio
338.61
Revenue / Employee
$55,404
Employees
99
Market Cap
1.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.13B |
| Immunocore Holdings | 430.78M |
| Vir Biotechnology | 303.23M |
| Syndax Pharmaceuticals | 252.25M |
| Maravai LifeSciences Holdings | 208.78M |
| Septerna | 98.88M |
| Intellia Therapeutics | 59.51M |
| Recursion Pharmaceuticals | 54.86M |
TSHA News
- 21 days ago - Taysha Gene Therapies Earnings Call Transcript: Q2 2026 - Transcripts
- 21 days ago - Taysha Gene Therapies Earnings release: Q2 2026 - Filings
- 21 days ago - Taysha Gene Therapies Quarterly report: Q2 2026 - Filings
- 21 days ago - Taysha Gene Therapies reports Q2 EPS (13c), consensus (11c) - TheFly
- 21 days ago - Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 26 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies, Catalent announce commercial supply pact for TSHA-102 - TheFly